Summary
- Gilead Sciences, Inc., an American biotechnology
company with international operations and twenty-plus innovative products, centers on discovering, developing, and commercializing treatments for a range of conditions (e.g., hep C, HIV).
- After a year of increased revenue and product sales, Gilead is well off; its assorted innovative, novel products, abundance of research activity, and international accessibility initiatives all strengthen the company.
- Harvoni and Sovaldi are particularly responsible for these positive trends; Gilead predicts that they will continue facilitating sales growth.
- The I Know First algorithm contradicts analysts and the fundamental outlook. Gilead poses a risk in the next month of a downswing; however, it holds strong long-term value investing.
Company Profile: Gilead Sciences, Inc.
Gilead Sciences (NASDAQ:
GILD) is an American biotechnology company that is involved in drug discovery, development, and commercialization, centering on treatments for HIV, hepatitis B, influenza, an assortment of pulmonary, liver, and cardiovascular diseases, cancer, and - most recently - hepatitis C. Initially founded in California, the company now has operations across North America, Europe, and Australia, and boasts an impressively diverse product line (to be specific, the company produces approximately twenty therapies, some of them wildly successful (
e.g., Sovaldi), and each with a slightly different focus).
